Keros Therapeutics Announces $5 Million Share Repurchase Program
Keros Therapeutics (KROS) has officially launched a new share buyback program valued at $5 million. The company stated that the execution of these repurchases will be determined by several variables, including current market prices for its common stock, broader economic conditions, and existing contractual limitations. The announcement follows a recent $20 million milestone achieved by the company. While the specific timing and volume of the buybacks remain flexible, the move signals management's intent to utilize capital toward returning value to shareholders or managing equity structure.

Tickers: $KROS
Topics: capital allocation share repurchase
Read the full article at Seeking Alpha
Part of the story China Automotive Systems Reports Record Q3 2026 EPS Unit Sales and $5 Million Share Repurchase Program (7 articles)